Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of…
In a groundbreaking advancement that could redefine therapeutic strategies against liver cancer, researchers have unveiled a potent combination of radiotherapy…